These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 39034958)
1. Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma. Wang Z; Chen X; Li Y; Qin J; Fang Y; Yang Z; Fang Y; Qu D; Zhang R; Zheng Q; Kang X; Xue L; Huang J; Li Y; He J J Natl Cancer Cent; 2022 Jun; 2(2):98-105. PubMed ID: 39034958 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study). Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study. Sheng Y; Meng X; Zhang C; Shan Z; Li F; Wu B; Xu M; Li A; Guan L; Chen L; Sun S; Ma Y; Lu T; Zhao S; Fan Q; Qi Y; Wang F J Thorac Dis; 2024 Aug; 16(8):5337-5347. PubMed ID: 39268120 [TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747 [TBL] [Abstract][Full Text] [Related]
5. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. Zhao J; Zhao L; Guo W; Wang S; Tao X; Li L; Mao Y; Tan F; Gao Y; Wu N; Ying J; Xue Q; Li N; Gao S; He J J Thorac Oncol; 2023 Jun; 18(6):780-791. PubMed ID: 36870519 [TBL] [Abstract][Full Text] [Related]
7. Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial. Wu Z; Wu C; Zhao J; Wu C; Peng H; Wang Q; Bai R; Fang X; He H; Shen H; Wu M EClinicalMedicine; 2024 May; 71():102579. PubMed ID: 38618203 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE). Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Qin J; Xue L; Hao A; Guo X; Jiang T; Ni Y; Liu S; Chen Y; Jiang H; Zhang C; Kang M; Lin J; Li H; Li C; Tian H; Li L; Fu J; Zhang Y; Ma J; Wang X; Fu M; Yang H; Yang Z; Han Y; Chen L; Tan L; Dai T; Liao Y; Zhang W; Li B; Chen Q; Guo S; Qi Y; Wei L; Li Z; Tian Z; Kang X; Zhang R; Li Y; Wang Z; Chen X; Hou Z; Zheng R; Zhu W; He J; Li Y Nat Med; 2024 Sep; 30(9):2549-2557. PubMed ID: 38956195 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study. Wang J; Zhang J; Gao J; Zhao M; Ma Z Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study. Zhou RQ; Luo J; Li LJ; Du M; Wu QC BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374 [TBL] [Abstract][Full Text] [Related]
13. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy. Qiao Y; Zhao C; Li X; Zhao J; Huang Q; Ding Z; Zhang Y; Jiao J; Zhang G; Zhao S Front Immunol; 2022; 13():953229. PubMed ID: 35911723 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial. Yang B; Guo X; Le C; Su W; Li X; Zhang Y; Yang G; Liang W; Zheng Z; Wu J; Zhang Y; Hao A Biomed Res Int; 2022; 2022():4727407. PubMed ID: 35898681 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Wu D; Li Y; Xu P; Fang Q; Cao F; Lin H; Li Y; Su Y; Lu L; Chen L; Li Y; Zhao Z; Hong X; Li G; Tian Y; Sun J; Yan H; Fan Y; Zhang X; Li Z; Liu X Nat Commun; 2024 Mar; 15(1):2177. PubMed ID: 38467604 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol. Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer. Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]